2016 Speakers

María de los Angeles Lobos

2016_angeleslobos_headshot.jpgMaría de los Angeles Lobos holds a degree in Psychology and has a specialization in dual diagnosis.

She is the director of treatment center for problematic drug consumption of Dianova Chile with headquarters in Viña del Mar. Dianova is an international NGO, operates in 11 countries across Europe and the Americas, with programs and projects in the fields of education, youth, addiction prevention and treatment, and in the area of social and community development.

She has focused on gender approach, intervention and treatment for problematic drug consumption on womens.

Her key areas of expertise are gender issues, public policy for the treatment and rehabilitation of people with problematic drug use, HIV / AIDS and addictions, dual pathology and harm reduction.

Steve Berg

2016_berg_headshot.jpgSteve Berg is the Chief Financial Officer of O.penVAPE. He manages matters relating to finance, business development, investor relations, corporate strategy, PR and advocacy. In addition to more than 22 years of experience in investment banking and finance, Mr. Berg has been a proponent of medical cannabis for decades. He believes business can be a powerful platform to effect social and legal change. He found his calling after progressing from the world of big banks to working on the front lines of legal cannabis enterprise. Prior to joining O.penVAPE, Mr. Berg was a co-founder of the thriving ArcView Investor Network, where investors, policy groups, and the most promising cannabis companies cast deals to develop future leaders in the industry and expand patient and consumer access. As editor of ArcView Market Research's The State of Legal Marijuana Markets, Second Edition, the cannabis industry's leading independent market research report, Berg is an acclaimed expert on the economics and development of the legal marijuana industry.

Mark Blumenthal

2016_blumenthal_headshot.jpgMark Blumenthal is the Founder and Executive Director of the American Botanical Council (ABC), the leading independent, non-profit organization dedicated to disseminating accurate, reliable, and responsible information on herbs and medicinal plants.

He is the Editor/Publisher of HerbalGram, an international, peer-reviewed quarterly journal. For six years he was an Adjunct Associate Professor of Medicinal Chemistry at the University of Texas at Austin, College of Pharmacy, teaching the course "Herbs and Phytomedicines in Today's Pharmacy." Mark is the Senior Editor of the English translation of The Complete German Commission E Monographs–Therapeutic Guide to Herbal Medicines (1998), Herbal Medicine: Expanded Commission E Monographs (2000), The ABC Clinical Guide to Herbs (2003), and co-author of Rational Phytotherapy, 5th edition (2004). He has appeared on over 400 radio and television shows and has written over 500 articles, reviews and book chapters for many major publications. In 2010 he was awarded the prestigious Tyler Prize in honor of the late Purdue Professor Varro E. Tyler from the American Society of Pharmacognosy.

In 2008 he was awarded the “Natural Legacy” award from Natural Foods Merchandiser magazine and he has also been named to Natural Health Magazine’s Hall of Fame Award for “...opening America’s eye to the healing powers of herbs.” He has been a leader in the concerns for more rational regulations of herbal and natural product manufacturing, and education on plant-based medicines for over 40 years.

Marcel O. Bonn-Miller

2016_bonnmiller_headshot.JPGMarcel O. Bonn-Miller, Ph.D., is an Assistant Professor in the Department of Psychiatry at the University of Pennsylvania Perelman School of Medicine. He received his B.A. and Ph.D. in Clinical Psychology from the University of Vermont and was a Postdoctoral Fellow at Stanford University School of Medicine. Dr. Bonn-Miller has dedicated his career to understanding the interrelations between cannabis use and PTSD, with the aim of informing intervention and prevention strategies. Dr. Bonn-Miller is internationally recognized as a leading expert in the study of cannabis use among individuals with PTSD. He has received dozens of grants varying in focus from experimental laboratory-controlled to prospective outcome studies, has published well over 100 peer-reviewed empirical publications, and serves on the editorial boards of six scientific journals.

Alexander Campbell

2016_campbell_headshot.JPGAlexander Campbell is an attorney working and living in Massachusetts, and the author of The Medical Marijuana Catch-22: How the Federal Monopoly on Marijuana Research Unfairly Handicaps the Rescheduling Movement, published in 2015.  While in law school, Alex focused heavily on health law and worked at a Federally-Qualified Health Center and a new health insurance company in Boston.  Alex currently works for the Commonwealth of Massachusetts.

Stephen B. Corn, MD

2016_corn_headshot.jpegStephen B. Corn, MD is a board certified physician of Brigham and Women's Hospital and Children's Hospital, Boston, Massachusetts and Professor at Harvard Medical School. He specializes in anesthesiology, pain and perioperative medicine. He is also a prolific inventor and holds over 30 United States and international patents. His expertise in medical devices has resulted in his being named the first and only “Director of Clinical Innovation” for both Boston Children’s Hospital and Brigham & Women’s Hospital, Harvard Medical School.

Dr. Corn is the recipient of numerous awards and was named, “Champions in Health Care” by the Boston Business Journal. Dr. Corn was featured on CBS News Boston and San Francisco for clinical innovation and inventing a non-contact means to measure breathing and respiratory depression.

Dr. Corn co-founded TheAnswerPage.com in 1998 to provide daily education to doctors and other healthcare professionals. TheAnswerPage is read in over 120 countries, has granted well over 100,000 hours of AMA PRA Category 1 CME Credits™ and offers an industry-unique interactive crossword puzzle for a fun and effective learning experience. TheAnswerPage is a recognized leader in medical marijuana education and the sole provider of the required “New York State Practitioner Education-Medical Use of Marijuana Course” and the Florida Medical Society required state medical marijuana course.

Dr. Corn is proud to note that in 2014, he was named "Medical Professional of the Year" by the Americans for Safe Access (ASA) in Washington, DC.

Dr. Corn has donated technology appraised at over $6 million to Brigham & Women’s Hospital, Harvard Medical School and Women & Infant’s Hospital, Brown University.

Sebastien Cotte


Sebastien Cotte became actively involved in the field of medical marijuana in 2013 while seeking alternative treatments for his son Jagger who is suffering from a rare terminal genetic disease. Like many other families, Sebastien and his wife Annett became medical refugees in Colorado to access cannabis oil for Jagger but returned to Georgia in late 2015 to focus on the 2016 legislative session and the need for in state cultivation.

He is also completing a medical marijuana certification program offered by Americans for Safe Access and the Cannabis Training Institute. He is not only an active member in the medical marijuana community, but also serves as an ambassador for the United Mitochondrial Disease Foundation, an organization that provides education, awareness and resources to health care professionals, patients and families affected by Mitochondrial disease.

Sebastien is the national business director/board member for the Flowering Hope Foundation (a 501c non for profit that provides education and patient support for Haleigh’s Hope products) and he is on the board of advisor for MdHerb, an educational website that focuses on cannabis patients. In his free time, Sebastien is a guest host of the Cannatics political show on Millennium Grown Broadcast Network.

Tjalling Erkelens

2016_erkelens_headshot.pngTjalling Erkelens, CEO Bedrocan BV The Netherlands.  Born in 1956 in The Netherlands, where he still lives, Tjalling studied to be a teacher before starting his career as a freelance journalist in 1976 , with a particular interest in agriculture and horticulture. In 1984, he married farmer’s daughter Wupke Bruining, and together they raised three sons. That same year he and his brother in law, Freerk Bruining, started a horticultural company  now known as Bedrocan B.V.  Over the years the company developed into a highly specialized, horticultural firm specializing in indoor cultivation and processing of plant material under standardized conditions. In 1992 Tjalling and Freerk started pioneering indoor cannabis grow for he purpose of seed production. In 2003, their work was acknowledged by the Dutch Health Ministry, which awarded Bedrocan the first five-year contract to cultivate medicinal cannabis for distribution through pharmacies.  Under Tjallings’ leadership the company turned into a multinational with licensed facilities up and running in The Netherlands, Canada and The Czech Republic with a joint annual capacity of about 5500 kilograms of cannabis. While operating under GAP and ISO 9001-2008 standards, the Dutch and Czech facilities are now the first ones to be GMP approved by the health authorities in the respective countries for production of cannabis flos as a fully standardized  pharmaceutical raw material.

Lumir Hanuš

2016_hanus_headshot.jpgDr. Lumír Ondřej Hanuš is a Czech analytical chemist and a leading authority in the field of cannabis research. In 1992, he and William Anthony Devane isolated and first described the structure of anandamide, an endogenous cannabinoid neurotransmitter. Dr. Hanuš is a research fellow at the Hebrew University in Jerusalem, Israel. He has been awarded honorary Doctoral degrees – including Chemiae Doctor honoris causa (2007) and Medicinae Doctor honoris causa (2011), the Hanuš Medal (2005), the Addictology Award (2012), and Olomouc City Award (2013). His major research interests cover the chemistry of natural products (the isolation and identification of new compounds from plants and animals) and the testing of compounds for biological activity.

John Hudak

2016_hudak_headshot.jpgJohn Hudak is a Senior Fellow in Governance Studies and Deputy Director at the Center for Effective Public Management at the Brookings Institution. His research focuses on presidential power, bureaucratic process, campaigns and elections. He has written extensively on questions of governance, regulation, and administration with regard to marijuana legalization policy. He is the author of the forthcoming book Marijuana: A Short History. John holds a B.A. in political science and economics from the University of Connecticut, and an M.A. and Ph.D. in political science from Vanderbilt University.

Pavel Kubů

2016_kubu_headshot.jpgPavel Kubů MD is the expert in the medical informatics and addictology. 2001 graduated in general medicine with a focus on diseases prevention and public health at Charles University in Prague, 3rd Medical Faculty.

Between 2005 and 2015 was working for Intel Corporation as the Business Development Manager. He was leading projects of Intel World Ahead Program for Healthcare in Central and Eastern Europe and Education in the Czech Republic and Slovakia.

In 2006 appointed as chairman of the Ethical Commission at the Czech National Monitoring Center for Drugs and Drug Abuse. This government agency is among others responsible for evaluation of ethical conditions and human rights compliance in all R&D project related to illegal drug use requesting public fundings.

Serves since 2007 as the board member of the Czech National Forum for eHealth, between 2012 and 2015 as the steering committee member of Czech Healthcare Forum and from 2013 as the board member of medical cannabis patient organization KOPAC. In March 2015 became founding member of International Medical Cannabis Patient Coalition. He is primarily devoted to education of healthcare professionals, patients and caregivers and support of research and development of new treatment and preventive methods in these non profit NGOs.

Since 2011 leads medical strategy implementation at co-founded company Elon Medical devoted to R&D of wearable plastic electronics actually using printed light and smart nanotechnologies in new treatment methods for dermatology, neonatology, mental health oncology, ophthalmology and surgery.

December 2015 founded with colleagues International Cannabis and Cannabinoids Institute and become Chief Executive Officer of research and innovation hub focused on clinical knowledge, services and tools development for implementation in clinical practise of new treatment methods using whole-plant medical cannabis in combination with personalized medicine tools and integrated care methods.

Cynthia Ludwig

2016_ludwig_headshot.jpgCynthia Ludwig, Director, Technical Services of AOCS, an association that provides technical and scientific resources to the oils, fats, lipids, proteins, surfactants and related industries, is responsible for all Technical Services activities including methods development, ISO Guide 34 accredited Certified Reference Material Program, laboratory proficiency programs, and AOCS accreditations.

Ludwig joined AOCS in 2014. Cynthia has a diverse background and long career as a research scientist. She started her journey as a large scale production and analytical chemist at Sigma-Aldrich in St. Louis, MO. After five years, she joined Monsanto where she spent the next 20 years contributing to over 20 patents, receiving numerous awards and developing new products and technologies. Roundup® production, Celebrex®, Bextra®, Paracoxib, and Decisive and Chipping Technologies are a few of the projects she influenced. Her degrees include a BS in Organic Chemistry from Southern Illinois University and an MS in Physical Organic Chemistry from Eastern Illinois University.

She lives with her small dog Gracie and splits her time between St. Louis MO and Champaign IL.

Ryan C. Lynch, PhD

2016_lynch_headshot.jpgRyan has broad experience with DNA sequencing and analysis technologies—ranging from microbes to prairie grasses to sunflowers. In 2014 he helped launch a Cannabis genome research project at the University of Colorado Boulder. Since completing his Cannabis-based PhD, he has operated a genomics and plant breeding consultancy, and most recently joined Medicinal Genomics. In his current role, he continues to develop genome sequencing technologies for Cannabis cultivators and breeders. These efforts have provided new insight into the diversity and origins many Cannabis varieties from around the globe, and have broad implications for improving the effectiveness and safety of Cannabis-based therapies.

Ian McGregor

2016_mcgregor_headshot.jpgIain McGregor is Professor of Psychopharmacology, NHMRC Principal Research Fellow and Director of the Psychopharmacology Laboratory at the University of Sydney.
Iain's research focuses on the effects of recreational drugs and prescription drugs on brain and behavior and also involves development of new medications for the treatment of various diseases. His research spans medicinal chemistry, the use of cellular assays and preclinical animal models of disease, and also clinical trials in humans.
Major recent areas of research interest include the beneficial effects of oxytocin on social behavior, the development of novel treatments for addiction-related and mental health problems, and analysis of the increasing use of prescription psychotropic drugs in Australia and other countries.
Iain has a strong interest in the area of medicinal cannabis and cannabinoids and is Director of Preclinical Research at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, Australia. The Lambert Initiative was established in 2015 with a $33.7 million philanthropic gift and aims to fast track research into the therapeutic benefits of cannabinoids in various disease states.

Pavel Pachta

2016_pachta_headshot.jpgDr. Pavel Pachta is an expert in international drug regulation. An economist by education, he lectured at the University of Economics in Prague, Czech Republic, and then served for more than two decades in various positions in the UN drug control bodies. He was between 2004 and 2013 the Deputy Secretary of the International Narcotics Control Board (INCB) at its Headquarters in Vienna, Austria. Dr. Pachta contributed to several UN and WHO publications on substances under international control and their availability for medical and scientific purposes. He has been a drug regulatory control consultant and he lectures internationally on the control of cannabis and cannabinoids. Dr. Pachta is member of the Scientific Board of the International Cannabis and Cannabinoids Institute in Prague. He is member of the Czech Patients Association for Cannabis Treatment "KOPAC".

Jeffrey C. Raber Ph.D.

2016_raber_headshot.jpgDr. Jeffrey C. Raber received his B.S. in biochemistry from Lebanon Valley College, PA and subsequently a Ph.D. in organic chemistry from the University of Southern California with an emphasis on developing new synthetic methodologies useful in pharmaceutical drug discovery and manufacturing. Dr. Raber studied botanical phylogenetic relationships based on the RuBisCO enzyme’s evolution while in college and was named to the USA Today 1997 All-USA College Academic Team for his research accomplishments in this area. While at USC he was awarded the Harold and Lillian Moulton Fellowship for his efforts on the construction of novel heterocycles and peptidomimetics utilizing a proprietary boron-based multicomponent condensation reaction. Since graduate school Dr. Raber has pursued various entrepreneurial endeavors highlighted by KinetiChem where he guides the development and commercialization of a novel continuous flow chemical reactor technology positioned at the forefront of what is called process intensification. Dr. Raber initially joined KinetiChem as the Chief Chemist and quickly became the Vice President and eventually the President and is currently on the company’s Board of Directors. Dr. Raber has numerous peer-reviewed publications, including 5 on cannabis chemistry, he has given invited lectures around the world and is also an inventor of multiple patented technologies. Driven by a desire to make a positive contribution to society while creating American jobs Dr. Raber founded The Werc Shop in 2010, an independent laboratory focused on botanical analysis, product development and sustainability with an initial emphasis on serving the unmet public health and safety needs within the medical cannabis community. Dr. Raber’s detailed investigations into the chemistry of cannabis as a medicine have provided him with a unique perspective and knowledgebase useful in assisting state and local regulators in the construction and implementation of effective regulatory solutions for the safe and sustainable delivery of medical cannabis to qualified patients. Today The Werc Shop is widely recognized as a leading scientific pioneer and educator in medical cannabis that continues to further everyone’s understanding of the plant and its possible product developments. The Werc Shop being guided Dr. Raber is recognized as leading the way towards chemotype designations for strain identification and are creating standardized broad- profile based derivative products through utilization of their innovative solvent-free concentrate processing methods coupled to a novel terpene infusion methodology which allows for the creation of unique and effective cannabis products across many therapeutic categories.

Ethan Russo

2016_russo_headshot.jpgEthan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system (“ECS”). The PHYTECS team pioneered scientific understanding of how the ECS regulates physiological functions including immunity, pain, inflammation, mood, emotion, learning, memory, metabolism, appetite, weight, sleep, embryo development, neuroprotection and stress responses.

Previously, from 2003-2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy.

He graduated from the University of Pennsylvania (Psychology) and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child and Adult Neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with the Machiguenga people in Parque Nacional del Manu, Peru. He joined GW as a full-time consultant in 2003. 

He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences. 

He is currently Past-President of the International Cannabinoid Research Society, and is former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over thirty articles in neurology, pain management, cannabis, and ethnobotany. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, and phytocannabinoid/terpenoid, /serotonergic and /vanilloid interactions.

Jeanne Sauro

2016_sauro_headshot.jpgMy name is Jeanne Sauro and I am living with Stage IV Metastatic Breast Cancer. Since becoming a cancer patient I have studied cannabis medicine extensively to treat my cancer and side effects from cancer treatments. I was the first registered student at the first cannabis vocational school in Massachusetts. The name is Northeastern Institute of Cannabis, Natick, MA. I took 11 courses pertaining to medical marijuana. Once I learned about this amazing plant and how it can ease the suffering and even cure some illnesses, I have become a tenacious and driven Medicinal Cannabis Activist. I am currently a Patient Advisory Board Member with Massachusetts Patient Advocacy Alliance and I am working with American’s For Safe Access more and more on the national level. I am on the front lines of medicinal marijuana in the state of Massachusetts and am aware of the challenges we face every day being a medical marijuana patient. It has not been easy, but helping to move this important medicine and treatment forward and make it available to all patients is what keeps me going. We are working hard and we are making progress slowly but surely. But we are making History!

Christine Stenquist

2016_stenquist_headshot.jpgChristine Stenquist is a brain tumor patient turned medical cannabis advocate. In 1996, she was diagnosed with an Acoustic Neuroma and removal was attempted; 60% of the tumor remains and with it a host of complications. After a decade and a half of a house-bound and bedridden life she approached her doctor about medical cannabis. Finding cannabis to mitigate most of her symptoms she sought out how to gain access. Being a daughter of a narcotics officer she was faced with the dilemma, break the law or change the law. Utah had passed a highly restrictive CBD only law when She started Drug Policy Project of Utah, a nonprofit dedicated to policy to champion legal access to cannabis in the state of Utah. In 2015, she lobbied and testified in support of SB259 Medical Cannabis Act, which failed in the Senate by one vote. After this narrow loss, Christine’s passion was further ignited to see cannabis legislation passed within the State of Utah, and she was determined to make an even greater impact during the following legislative session. Realizing the need for patient lobbyists on Capitol hill, the citizen lobbyist group, TRUCE, Together for Responsible Use and Cannabis Education, was formed to help raise awareness for the need of safe, legal access to cannabis. In the 2016 legislative session, Christine brought patient and caregivers from differing ideologies and conditions together to effectively lobby in support of SB 73, Medical Cannabis Act, outcome yet to be determined. Federal rescheduling of cannabis has also become an area of interest for Christine.

Dustin Sulak

2016_sulak_headshot.jpgDr. Dustin Sulak is an integrative medicine physician with expertise in osteopathy, mind-body medicine, and medical cannabis. His clinical practice focuses on treating refractory conditions in adults and children with an individualized, health-centered approach. Dr. Sulak received undergraduate degrees in nutrition science and biology from Indiana University, a doctorate of osteopathy from the Arizona College of Osteopathic Medicine, and completed an osteopathic rotating internship at Maine-Dartmouth Family Medicine Residency. Dr. Sulak is the founder of Integr8 Health, an integrative medicine clinic with 3 locations in New England that treat over 18,000 patients with medical cannabis. He is also the founder of Healer.com, an education and research portal for medical cannabis patients. Dr. Sulak lectures nationally to physicians on the clinical application of cannabinoids and continues to pioneer this emerging field in medicine.

Ryan Vandrey, Ph.D.

2016_vandrey_headshot.JPGDr. Vandrey is an experimental psychologist with degrees from the University of Delaware (BA) and University of Vermont (PhD). He is currently an Associate Professor at the Johns Hopkins University Behavioral Pharmacology Research Unit (BPRU). He has received research grants and contracts from multiple federal agencies, private industry, and non-profit organizations. Dr. Vandrey’s research focuses on the behavioral pharmacology of cannabis (marijuana). His research primarily consists of controlled laboratory studies with adult research volunteers, but also includes clinical trials, web-based survey research, and natural history studies with patient populations using cannabis/cannabinoids for therapeutic purposes. Prior research includes laboratory studies characterizing the cannabis withdrawal syndrome, evaluation of the comparative pharmacokinetics and corresponding pharmacodynamics of cannabinoids across routes of administration, exploring medications that can be used as adjuncts to behavior therapy to improve rates of abstinence among individuals trying to quit using cannabis, examining the effects of cannabis on sleep, and conducting research designed to help evaluate the safety and efficacy of medicinal use of cannabis/cannabinoids for specific health conditions.

Boaz Wachtel

2016_wachtel_headshot.pngBoaz Wachtel is an Initiator (1995-2013) and co-strategist with Israel’s Ministry of Health (MOH) of Israel’s Medical Cannabis program that currently includes over 11,000 patients served by eight specialist physicians authorized to issue licenses and eight licensed cultivators. A researcher on addiction, harm reduction, and cannabis, he has published more than two dozen articles, papers, and book chapters. He was a founding member of the 'Israeli Foundation for Drug Law Reform' (1994) and a public representative to the Knesset (Israeli Parliament) Drug Committee “Examining the legal status of Cannabis.” He submitted to the MOH the cannabis 'Drug Master File' (safety and efficacy data) and has since represented patients to the MOH which established in 1999 a committee to review requests and provide licenses for patients to possess medicinal cannabis. He was a co-producer with Maripharm Holland of "The Medicinal Uses of Cannabis" from 2000-2002, and an organizer with MOH of the Medical Cannabis Education Seminar for Doctors in 2007. In 2009, he became a founding member (volunteer) of the Centralized National Medical Cannabis distribution Center in Abarbanel Hospital. He has been a Member of the Board of the Israeli AIDS committee since 2006 and is a Member of the Steering Committee of ENCOD, the European Coalition for Just and Effective Drug Policies. He is a founder and former Chairman (1999-2006) of Israel’s Green Leaf Party, which won 1% of the national vote in 1999, 1.2% in 2003 and 1.4% in 2006. He was an addiction treatment provider using Ibogaine (1989-2000) and co-author, with Howard Lotsof, of the "Ibogaine - Treatment Manual." He currently works developing agricultural technologies. Boaz is a Certified Clinical Research Administrator with Israel’s MOH and Bar-Ilan University, and is a certified Consultant with the EU Research & Development Program at Tel Aviv University. He served as Assistant Army Attaché' in the Israeli Embassy in DC from 1983-1988.

Grace Wallack

2016_wallack_headshot.jpgGrace Wallack is a Senior Research Assistant at the Center for Effective Public Management at The Brookings Institution and Associate Editor of the FixGov blog. She works on regulatory policy,presidential and congressional elections, and institutional effectiveness. She is the co-author, with John Hudak, of the report, “Ending the U.S. government’s war on medical marijuana research.” She holds a B.A. in American Studies from Georgetown University.

Melissa Wilcox

2016_wilcox_headshot.JPGMelissa Wilcox is a Global Marketing Manager for Grace Discovery Sciences. She has more than 20 years experience in chromatographic separations, with expertise in analytical chromatography and purification technologies. She holds patents on evaporative light scattering detection technology and is involved in research and development, applications development, business development, and marketing. Melissa is a co-founder and Counselor for the American Chemical Society (ACS) Cannabis Chemistry subdivision (CANN) and a member of the American Oil Chemists Society (AOCS) and American Herbal Products Association (AHPA) cannabis expert panels. She is part of a collaborative research team working to develop better analytical methods for cannabis products to ensure patient safety, focusing on sample preparation of edible products with complex matrices.

Jane Wilson

2016_wilson_headshot.jpgJane Wilson is the Director of Program Development for the American Herbal Products Association (APHA) where her duties include working with the AHPA management team to develop, implement, and manage AHPA programs and services. She brings to this role many years of experience developing cooperative relationships with representatives of industry, trade associations, public health officials, regulatory bodies, advocacy groups, and other stakeholders.

Since joining the staff of AHPA in 2013, Jane has been providing staff support to the AHPA Cannabis Committee in its development of a series of “Recommendations to Regulators” documents that define best practices for the cannabis industry from seed to consumer. These documents are being provided to regulators in states where use of cannabis has been legalized so that regulatory authorities can consider the adoption of these recommendations, in whole or in part, as the basis for development of jurisdiction-specific regulations. These documents also provide the foundation for the ASA Patient Focused Certification (PFC) Program and can be used by those in the cannabis industry seeking to self-regulate on cannabis product safety and quality.

Jane has more than 25 years of experience in various positions related to protection of public health and the environment. She holds a Master of Public Health degree in Toxicology and a Bachelor of Science degree in Medical Technology, both earned at the University of Michigan.

get updates